AEZS-125 induces inhibition of cell growth of triple negative breast cancer via binding to GnRH receptor

Introduction: Receptors of gonadotropin-releasing hormone (GnRH), also regarded as luteinizing hormone-releasing hormone (LHRH), are found to be expressed in triple negative breast cancer (TNBC), which contributes to approximately 10 to 20% of breast cancer. Selective targeting of the GnRH receptors is a promising approach in breast cancer therapy. AEZS-125 is a Disorazol-Z conjugate linked to the GnRH receptor agonist D-Lys6-LHRH. Disorazol-Z is a novel natural cytotoxic compound isolated from the myxobacterium Sorangium cellulosum. Owing to the binding affinity of the D-Lys6-LHRH peptide to the GnRH receptors,…